HEADLINE AT-A-GLANCE
- 95% of patients had near-zero heart valve leaks after one year
- Helps people with severe or massive tricuspid valve leaks
- Still requires surgery but avoids open-heart procedures
QUICK TAKE A new minimally invasive valve replacement slashes hospital stays for severe heart leak patients especially those with the worst cases new long-term data shows
SEO TITLE EVOQUE Valve Fix Reduces Heart Failure Hospitalizations
SEO DESCRIPTION People with severe tricuspid valve leaks see fewer hospital stays after minimally invasive replacement with best results for massive leaks study finds
ARTICLE BODY Mary felt like she was drowning on dry land. Every step left her gasping for air. Her doctor said it was her heart valve leaking badly. She was not alone.
Millions struggle with tricuspid regurgitation. That is when a heart valve leaks blood backward. It causes swelling tiredness and trouble breathing. Current treatments often fail especially for severe cases. Many patients face risky open-heart surgery.
But here is hope. A new device called EVOQUE offers a gentler solution. It works like a tiny plug inside the heart. Doctors thread it through a leg vein. No chest opening needed.
Why the Leak Matters Most This valve leak is sneaky. It makes your heart work harder. Fluid builds up in your belly and legs. Old treatments just managed symptoms. They did not fix the leak itself.
Think of your heart like a water pump. A bad valve is like a broken seal. Water sprays everywhere instead of flowing forward. The EVOQUE device seals that leak. It acts like a new washer in a faucet. Simple and effective.
The TRISCEND II trial tested this idea. It studied 400 people with severe or massive valve leaks. Two hundred sixty seven got the EVOQUE device plus standard care. One hundred thirty three got standard care alone. All were followed for over a year.
Results brought real relief. One year later 95% of patients had only mild or no leaks. Their breathing improved. They walked farther. They felt less swollen. Quality of life scores jumped significantly.
The biggest win was fewer hospital trips. Patients with massive leaks saw hospital stays for heart failure drop by 15%. That is one less trip for every seven patients. Imagine that freedom.
But there is a catch.
This procedure is not yet available at most hospitals. It requires special training and equipment. Also survival rates were similar between groups. The real victory was better daily living.
Experts see this as a turning point. For years heart doctors focused only on the main heart valves. The tricuspid valve was ignored. This trial proves fixing it matters deeply.
What This Means For You If you have severe tricuspid regurgitation talk to your doctor. Ask if you might qualify for this procedure. It is not right for everyone. You need good overall heart function. The device works best when the main heart muscle is still strong.
The study had limits. It only followed patients for 18 months. Longer data is needed. Also the trial excluded very sick patients. Real world results might differ.
The FDA will review these results this fall. Wider availability could come in 2027 if approved. More studies are already testing the device in even sicker patients.
Heart doctors are cautiously excited. This is not a cure but it offers real hope. For people like Mary it means breathing easy again. Walking to the mailbox without stopping. Living life instead of fighting symptoms. That is a change worth waiting for.